ClinicalTrials.govpublic full text
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
lupus erythematosus, systemic, atacicept 75 and 150 mg, lte, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1033335
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.